MiMedx Group Inc (MDXG):製品パイプライン分析

GlobalDataが発行した調査報告書(GDME83319PD)
◆英語タイトル:MiMedx Group Inc (MDXG) - Product Pipeline Analysis, 2020 Update
◆商品コード:GDME83319PD
◆発行会社(リサーチ会社):GlobalData
◆発行日:2021年1月
◆ページ数:42
◆レポート形式:英語 / PDF
◆納品方法:Eメール
◆調査対象地域:United States
◆産業分野:Medical Devices
◆販売価格オプション(消費税別)
Site License(同一事業所内共有可)USD1,500 ⇒換算¥165,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD2,250 ⇒換算¥247,500見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規代理店です。同社発行の市場リサーチレポート及びリサーチサービスに関するお問い合わせは弊社までお願い致します。GlobalData社の概要及び新刊レポートはこちらでご確認いただけます。

【レポートの概要】

Summary
MiMedx Group Inc (MiMedx) is a biopharmaceutical company that develops, manufactures and markets regenerative biologics utilizing human placental allografts. The company provides products such as amniotic membrane, umbilical cord, placental ECM and amniotic fluid. It utilizes proprietary purion process that separates placental tissues, cleans and reassembles layers, and dehydrates the tissue to preserve the key elements associated with healing. MiMedx’s product delivers human extracellular matrix components for regeneration of damaged or diseased tissues. Its products modulate inflammation, reduce scar tissue formation, and enhance healing. The company offers services in the areas of wound care, burn, surgical, orthopaedic, spine, sports medicine, ophthalmic and dental sectors of healthcare. MiMedx is headquartered in Marietta, Georgia, the US.

This report is a source for data, analysis, and actionable intelligence on the company’s portfolio of pipeline products. The report provides key information about the company, its major products and brands.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage.

Scope:

- The report reviews detailed company profile with information on business description, key company facts, major products and services, key competitors, key employees, locations and subsidiaries and recent developments
- The report analyzes all pipeline products in development for the company MiMedx Group Inc
- The report provides pipeline analysis on all pipeline products of the company (by equipment type, by indication, by development stage, and by trial status)
- The report covers detailed information on each pipeline product with information on pipeline territory, stage of development, device class, regulatory path, indication(s), application(s) and estimated launch date
- The report provides detailed description of products in development, technical specification and functions
- The report also covers ongoing clinical trials (wherever applicable) with information on trial name, trial objective, sponsor, trial design , trial status and phase, estimated start and end date.

Reasons to Buy:

- Develop business strategies by understanding the trends and developments driving the medical devices pipeline and technology landscape
- Design and develop your product development, marketing and sales strategies by understanding the competitor portfolio
- To formulate effective Research & Development strategies
- Develop market-entry and market expansion strategies
- Exploit in-licensing and out-licensing opportunities by identifying products, most likely to ensure a robust return
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop competition strategies by identifying the status and likely launch of the competitors’ pipeline products through review of the clinical trials, stage and of development, etc
- Identify, understand and capitalize the next high-value products that your competitor would add in its portfolio

Note: Some sections may be missing if data is unavailable for the company

【レポートの目次】

Table of Contents
List of Tables
List of Figures
MiMedx Group Inc Company Overview
MiMedx Group Inc Company Snapshot
MiMedx Group Inc Pipeline Products and Ongoing Clinical Trials Overview
MiMedx Group Inc – Pipeline Analysis Overview
MiMedx Group Inc – Key Facts
MiMedx Group Inc – Major Products and Services
MiMedx Group Inc Pipeline Products by Development Stage
MiMedx Group Inc Ongoing Clinical Trials by Trial Status
MiMedx Group Inc Pipeline Products Overview
AmnioFix Injectable – Achilles Tendonitis
AmnioFix Injectable – Achilles Tendonitis Product Overview
AmnioFix Injectable – Achilles Tendonitis Clinical Trial
AmnioFix Injectable – Knee OA Pain
AmnioFix Injectable – Knee OA Pain Product Overview
AmnioFix Injectable – Knee OA Pain Clinical Trial
AmnioFix Injectable – Plantar Fasciitis
AmnioFix Injectable – Plantar Fasciitis Product Overview
AmnioFix Injectable – Plantar Fasciitis Clinical Trial
AmnioFix Injectable – Pressure Ulcer
AmnioFix Injectable – Pressure Ulcer Product Overview
CollaFix – Foot & Ankle
CollaFix – Foot & Ankle Product Overview
CollaFix – Rotator Cuff Repair
CollaFix – Rotator Cuff Repair Product Overview
CollaFix BioBraid
CollaFix BioBraid Product Overview
CollaFix Collagen Fiber Suture
CollaFix Collagen Fiber Suture Product Overview
CollaFix Tendon Protector
CollaFix Tendon Protector Product Overview
EpiFix Amniotic Membrane Allograft
EpiFix Amniotic Membrane Allograft Product Overview
EpiFix Amniotic Membrane Allograft Clinical Trial
SaluDisc
SaluDisc Product Overview
MiMedx Group Inc – Key Competitors
MiMedx Group Inc – Key Employees
MiMedx Group Inc – Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries
Recent Developments
MiMedx Group Inc, Recent Developments
Jul 28, 2020: MiMedx adds Rohit Kashyap, Ph.D., to leadership team as Executive Vice President and Chief Commercial Officer
Apr 06, 2020: MiMedx Group agrees to pay $6.5 million to resolve false claims act allegations of false commercial pricing disclosures
Dec 16, 2019: MiMedx Announces addition of Peter M. Carlson
Nov 26, 2019: SEC charges biotech company and executives with accounting fraud
Nov 26, 2019: MiMedx names William “Butch” Hulse as General Counsel and Secretary
Nov 26, 2019: MiMedx announces Securities and Exchange Commission Settlement
Sep 20, 2019: MiMedx announces resignation of board member
Jun 05, 2019: MiMedx issues new presentation for investors in advance Of 2018 Annual Meeting
May 30, 2019: MiMedx announces comprehensive board refreshment plan in cooperation with prescience point
May 09, 2019: MiMedx appoints Timothy R. Wright as Chief Executive Officer
Appendix
Methodology
About GlobalData
Contact Us
Disclaimer

List of Tables
MiMedx Group Inc Pipeline Products and Ongoing Clinical Trials Overview
MiMedx Group Inc Pipeline Products by Equipment Type
MiMedx Group Inc Pipeline Products by Indication
MiMedx Group Inc Ongoing Clinical Trials by Trial Status
MiMedx Group Inc, Key Facts
MiMedx Group Inc, Major Products and Services
MiMedx Group Inc Number of Pipeline Products by Development Stage
MiMedx Group Inc Pipeline Products Summary by Development Stage
MiMedx Group Inc Ongoing Clinical Trials by Trial Status
MiMedx Group Inc Ongoing Clinical Trials Summary
AmnioFix Injectable - Achilles Tendonitis - Product Status
AmnioFix Injectable - Achilles Tendonitis - Product Description
AmnioFix Injectable - Achilles Tendonitis - A Phase III Achilles Tendonitis Clinical Study of Investigational New Drug (IND)
AmnioFix Injectable - Knee OA Pain - Product Status
AmnioFix Injectable - Knee OA Pain - Product Description
AmnioFix Injectable - Knee OA Pain - A Phase IIb, Prospective, Double-blinded, Randomized Controlled Study of Regenerative Medicine Advanced Therapy (RMAT) Designated AmnioFix Injectable in the Treatment of Knee Osteoarthritis
AmnioFix Injectable - Plantar Fasciitis - Product Status
AmnioFix Injectable - Plantar Fasciitis - Product Description
AmnioFix Injectable - Plantar Fasciitis - Prospective, Double-blinded, Randomized Controlled Trial of AmnioFix Injectable as Compared to a Saline Placebo Injection in the Treatment of Plantar Fasciitis
AmnioFix Injectable - Pressure Ulcer - Product Status
AmnioFix Injectable - Pressure Ulcer - Product Description
CollaFix - Foot & Ankle - Product Status
CollaFix - Foot & Ankle - Product Description
CollaFix - Rotator Cuff Repair - Product Status
CollaFix - Rotator Cuff Repair - Product Description
CollaFix BioBraid - Product Status
CollaFix BioBraid - Product Description
CollaFix Collagen Fiber Suture - Product Status
CollaFix Collagen Fiber Suture - Product Description
CollaFix Tendon Protector - Product Status
CollaFix Tendon Protector - Product Description
EpiFix Amniotic Membrane Allograft - Product Status
EpiFix Amniotic Membrane Allograft - Product Description
EpiFix Amniotic Membrane Allograft - Clinical Evaluation of EpiFix in venous leg ulcers ("VLUs")
EpiFix Amniotic Membrane Allograft - Limb Salvage Through Tissue Engineering: A Novel Treatment Modality Using Dehydrated Human Amnion/Chorion Membrane
EpiFix Amniotic Membrane Allograft - The Registry of Cellular and Tissue Based Therapies for Chronic Wounds and Ulcers
SaluDisc - Product Status
SaluDisc - Product Description
MiMedx Group Inc, Key Employees
MiMedx Group Inc, Subsidiaries
Glossary

【免責事項】
http://www.globalresearch.jp/disclaimer

★リサーチレポート[ MiMedx Group Inc (MDXG):製品パイプライン分析(MiMedx Group Inc (MDXG) - Product Pipeline Analysis, 2020 Update)]についてメールでお問い合わせはこちらでお願いします。

◆H&Iグローバルリサーチのお客様(例)◆